Year archive

Valneva SE — 2024 filings

All 156 regulatory filings released by Valneva SE (VLA) in 2024, sourced directly from the official regulator.

156 Filings

2024 Period

2024 filings (156)

Filing	Released	Lang
FORM 6-K Foreign Filer Report	2024-12-19	English
Valneva accroît l’accessibilité de son vaccin contre le chikungunya en Asie grâce à une collaboration avec le Serum Institute of India Regulatory Filings	2024-12-19	French
Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India Regulatory Filings	2024-12-19	English
VALNEVA - Declaration of shares and voting rights: November 30, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-12-05	English
Déclaration d'actions et de droits de vote de la société Valneva SE - novembre 2024 Declaration of Voting Results & Voting Rights Announcements	2024-12-05	French
FORM 6-K Foreign Filer Report	2024-12-04	English
Franchissement de seuil Major Shareholding Notification	2024-12-04	French
Valneva annonce la publication dans le British Medical Journal d’un article sur l’impact sanitaire et économique mondial du chikungunya Regulatory Filings	2024-12-04	French
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal Regulatory Filings	2024-12-04	English
FORM 6-K Foreign Filer Report	2024-12-03	English
Valneva annonce des données positives sur la persistance des anticorps à trois ans pour son vaccin à dose unique contre le chikungunya, IXCHIQ® Regulatory Filings	2024-12-03	French
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Regulatory Filings	2024-12-03	English
FORM 6-K Foreign Filer Report	2024-11-26	English
Valneva soumet à la FDA une demande d’extension d’indication pour son vaccin contre le chikungunya IXCHIQ® Regulatory Filings	2024-11-26	French
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA Regulatory Filings	2024-11-26	English
FORM 6-K Foreign Filer Report	2024-11-13	English
Valneva et LimmaTech annoncent la vaccination du premier participant à l’essai d’infection contrôlée de Phase 2b du candidat vaccin tétravalent contre la shigellose S4V2 Regulatory Filings	2024-11-13	French
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 Regulatory Filings	2024-11-13	English
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences Report Publication Announcement	2024-11-12	English
Valneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en Europe Report Publication Announcement	2024-11-12	French
6-K Foreign Filer Report	2024-11-07	English
Valneva publie ses résultats financiers pour les neuf premiers mois de l’exercice 2024 et fait un point sur ses activités Earnings Release 9M 2024	2024-11-07	French
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates Earnings Release 9M 2024	2024-11-07	English
VALNEVA - Déclaration d’actions et de droits de vote : 31 octobre 2024 Declaration of Voting Results & Voting Rights Announcements	2024-11-06	French
VALNEVA - Declaration of shares and voting rights: October 31, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-11-06	English
FORM 6-K Foreign Filer Report	2024-10-21	English
Valneva effectuera des présentations sur le chikungunya lors de différentes conférences scientifiques de premier plan Regulatory Filings	2024-10-21	French
Valneva to Present on Chikungunya at Several Leading Scientific Conferences Regulatory Filings	2024-10-21	English
FORM 6-K Foreign Filer Report	2024-10-16	English
Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V Regulatory Filings	2024-10-16	English
Valneva and LimmaTech reçoivent le statut « Fast Track » de la FDA pour leur candidat vaccin tétravalent contre la Shigellose S4V Legal Proceedings Report	2024-10-16	French
FORM 6-K Foreign Filer Report	2024-10-10	English
Valneva organise une journée investisseurs aujourd’hui à New York Report Publication Announcement	2024-10-10	French
Valneva Hosts Investor Day in New York City Investor Presentation	2024-10-10	English
Valneva SE - Déclaration d’actions et de droits de vote - 30 septembre 2024 Declaration of Voting Results & Voting Rights Announcements	2024-10-04	French
Valneva SE - Declaration of shares and voting rights - September 30, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-10-04	English
FORM 6-K Foreign Filer Report	2024-10-03	English
Valneva organise une journée investisseurs à New York le 10 octobre 2024 Report Publication Announcement	2024-10-03	French
Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET Regulatory Filings	2024-10-03	English
Franchissement de seuil Major Shareholding Notification	2024-09-23	French
Franchissement de seuil Major Shareholding Notification	2024-09-23	French
SC 13D/A Major Shareholding Notification	2024-09-20	English
Franchissement de seuil Major Shareholding Notification	2024-09-19	French
Franchissement de seuil Major Shareholding Notification	2024-09-19	French
FORM 6-K Foreign Filer Report	2024-09-18	English
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada Regulatory Filings	2024-09-18	English
Valneva soumet des demandes d’élargissement de l’indication de son vaccin contre le chikungunya IXCHIQ® à l’EMA et Santé Canada Environmental & Social Information	2024-09-18	French
6-K Foreign Filer Report	2024-09-13	English
Valneva Announces the Success of its Private Placement Raising approximately €60 Million Capital/Financing Update	2024-09-13	English
Valneva annonce le succès de son augmentation de capital et lève environ 60 millions d’euros Capital/Financing Update	2024-09-13	French
Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros Capital/Financing Update	2024-09-12	English
Valneva annonce le lancement d’un projet d’augmentation de capital d’environ 60 millions d’euros Capital/Financing Update	2024-09-12	French
VALNEVA - Declaration of shares and voting rights: August 31, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-09-04	English
VALNEVA - Déclaration d’actions et de droits de vote : 31 août 2024 Declaration of Voting Results & Voting Rights Announcements	2024-09-04	French
FORM 6-K Foreign Filer Report	2024-09-03	English
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate Earnings Release FY 2024	2024-09-03	English
Valneva et Pfizer annoncent de nouvelles données positives de Phase 2 après une vaccination de rappel pour le candidat vaccin contre la maladie de Lyme Investor Presentation	2024-09-03	French
Franchissement de seuil Major Shareholding Notification	2024-08-30	French
6-K Foreign Filer Report	2024-08-13	English
VALNEVA HALF-YEAR FINANCIAL REPORT Interim / Quarterly Report H2 2024	2024-08-13	French
Valneva publie ses résultats financiers du premier semestre 2024 et fait un point sur ses activités Interim / Quarterly Report H1 2024	2024-08-13	French
Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates Earnings Release H1 2024	2024-08-13	English
VALNEVA - Declaration of shares and voting rights: July 31, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-08-06	English
VALNEVA - Déclaration d’actions et de droits de vote : 31 juillet 2024 Declaration of Voting Results & Voting Rights Announcements	2024-08-06	French
FORM 6-K Foreign Filer Report	2024-08-01	English
Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate Regulatory Filings	2024-08-01	English
Valneva et LimmaTech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au monde Regulatory Filings	2024-08-01	French
Franchissements de seuils Major Shareholding Notification	2024-07-24	French
FORM 6-K Foreign Filer Report	2024-07-22	English
CEPI renforce son partenariat avec Valneva en lui octroyant un nouveau financement de $41,3 millions visant à accroître l’accessibilité du premier vaccin au monde contre le chikungunya Regulatory Filings	2024-07-22	French
CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine Regulatory Filings	2024-07-22	English
FORM 6-K Foreign Filer Report	2024-07-18	English
Essai de Phase 3 VALOR sur la maladie de Lyme : Valneva et Pfizer finalisent la vaccination primaire de tous les participants Regulatory Filings	2024-07-17	French
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion Regulatory Filings	2024-07-17	English
Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024 Declaration of Voting Results & Voting Rights Announcements	2024-07-04	French
Declaration of shares and voting rights - Valneva SE - June 30, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-07-04	English
FORM 6-K Foreign Filer Report	2024-07-01	English
Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® Regulatory Filings	2024-07-01	English
Valneva reçoit une autorisation de mise sur le marché en Europe pour le premier vaccin au monde contre le chikungunya, IXCHIQ® Earnings Release FY 2024	2024-07-01	French
FORM 6-K Foreign Filer Report	2024-06-27	English
Valneva annonce l’approbation des résolutions présentées à son Assemblée Générale et la nomination d’un nouvel administrateur à son conseil d’administration AGM Information	2024-06-26	French
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board AGM Information	2024-06-26	English
FORM 6-K Foreign Filer Report	2024-06-24	English
Valneva annonce l’approbation par Santé Canada du premier vaccin au monde contre le chikungunya, IXCHIQ® Regulatory Filings	2024-06-24	French
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® Regulatory Filings	2024-06-24	English
FORM 6-K Foreign Filer Report	2024-06-05	English
Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction AGM Information	2024-06-05	French
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update AGM Information	2024-06-05	English
FORM 6-K Foreign Filer Report	2024-06-04	English
VALNEVA - Déclaration d’actions et de droits de vote : 31 mai 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-04	French
VALNEVA - Declaration of shares and voting rights: May 31, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-04	English
Valneva annonce sa participation à différentes conférences investisseurs du mois de juin Regulatory Filings	2024-06-04	French
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June Regulatory Filings	2024-06-04	English
FORM 6-K Foreign Filer Report	2024-06-03	English
Valneva annonce la publication de deux essais de Phase 2 sur la maladie de Lyme dans le Lancet Infectious Diseases Regulatory Filings	2024-06-03	French
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases Regulatory Filings	2024-06-03	English
FORM 6-K Foreign Filer Report	2024-05-31	English
Valneva reçoit un avis positif du CHMP pour une autorisation de mise sur le marché en Europe de son vaccin contre le chikungunya Regulatory Filings	2024-05-31	French
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine Regulatory Filings	2024-05-31	English
FORM 6-K Foreign Filer Report	2024-05-21	English
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer Board/Management Information	2024-05-21	English
Valneva annonce la nomination du Dr Hanneke Schuitemaker en tant que Directeur Scientifique Board/Management Information	2024-05-21	French
FORM 6-K Foreign Filer Report	2024-05-13	English
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine Earnings Release FY 2024	2024-05-13	English
Valneva annonce de nouveaux résultats positifs chez les adolescents pour l’étude pivot de Phase 3 de son vaccin à dose unique contre le chikungunya Earnings Release FY 2024	2024-05-13	French
6-K Foreign Filer Report	2024-05-07	English
Valneva publie ses résultats financiers du premier trimestre 2024 et fait un point sur ses activités Earnings Release Q1 2024	2024-05-07	French
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Earnings Release Q1 2024	2024-05-07	English
Déclaration d’actions et de droits de vote - 30 avril 2024 - Valneva SE Declaration of Voting Results & Voting Rights Announcements	2024-05-06	French
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE Declaration of Voting Results & Voting Rights Announcements	2024-05-06	English
Franchissement de seuil Major Shareholding Notification	2024-04-12	French
Déclaration d'actions et de droits de vote de la société Valneva SE - mars 2024 Declaration of Voting Results & Voting Rights Announcements	2024-04-04	French
Declaration of voting rights - Valneva SE, March 2024 Declaration of Voting Results & Voting Rights Announcements	2024-04-04	English
FORM 6-K Foreign Filer Report	2024-03-26	English
Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génération contre le virus Zika Regulatory Filings	2024-03-26	French
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F Report Publication Announcement	2024-03-25	English
20-F Annual Report FY 2023	2024-03-22	English
Document d'enregistrement universel 2023 Annual Report (ESEF) FY 2023	2024-03-22	French
Document d'enregistrement universel 2023 Annual Report (ESEF) FY 2023	2024-03-22	French
FORM 6-K Foreign Filer Report	2024-03-21	English
Valneva fera une présentation sur son vaccin contre le chikungunya, IXCHIQ®, et participera à plusieurs événements lors du 24ème World Vaccine Congress à Washington, D.C. Regulatory Filings	2024-03-21	French
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. Report Publication Announcement	2024-03-21	English
FORM 6-K Foreign Filer Report	2024-03-20	English
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook Earnings Release FY 2023	2024-03-20	English
Valneva publie ses résultats financiers 2023 et fait un point sur son activité et ses perspectives financières Earnings Release FY 2023	2024-03-20	French
FORM 6-K Foreign Filer Report	2024-03-18	English
Valneva annonce un report de la date de début de remboursement du prêt contracté avec les sociétés Deerfield et OrbiMed Capital/Financing Update	2024-03-18	French
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed Capital/Financing Update	2024-03-18	English
Franchissement de seuil Major Shareholding Notification	2024-03-12	French
Déclaration d’actions et de droits de vote de la société Valneva - 29 février 2024 Declaration of Voting Results & Voting Rights Announcements	2024-03-06	French
VALNEVA Declaration of shares and voting rights - February 29, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-03-06	English
FORM 6-K Foreign Filer Report	2024-03-04	English
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences Regulatory Filings	2024-03-04	English
Valneva fera une présentation lors des conférences investisseurs TD Cowen et Van Lanschot Kempen Regulatory Filings	2024-03-04	French
FORM 6-K Foreign Filer Report	2024-02-29	English
Le Comité consultatif sur la vaccination aux États-Unis (ACIP) recommande l’utilisation d’IXCHIQ®, le vaccin à injection unique contre le chikungunya de Valneva Regulatory Filings	2024-02-29	French
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ® Regulatory Filings	2024-02-29	English
FORM 6-K Foreign Filer Report	2024-02-15	English
Valneva publie son chiffre d’affaires et sa trésorerie pour l’exercice 2023 et fournit des indications préliminaires pour l’exercice 2024 Earnings Release FY 2023	2024-02-15	French
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance Earnings Release FY 2023	2024-02-15	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-02-14	English
VALNEVA : Déclaration d’actions et de droits de vote - 31 janvier 2024 Declaration of Voting Results & Voting Rights Announcements	2024-02-07	French
VALNEVA: Declaration of shares and voting rights - January 31, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-02-07	English
FORM 6-K Foreign Filer Report	2024-02-05	English
Valneva Announces Sale of Priority Review Voucher for $103 Million Regulatory Filings	2024-02-05	English
Valneva annonce la vente de son bon de revue prioritaire (PRV) pour 103 millions de dollars M&A Activity	2024-02-05	French
Franchissement de seuils Major Shareholding Notification	2024-01-18	French
Franchissement de seuils Major Shareholding Notification	2024-01-16	French
FORM 6-K Foreign Filer Report	2024-01-10	English
Valneva vaccine le premier participant de l’étude pédiatrique portant sur son vaccin à dose unique contre le chikungunya Regulatory Filings	2024-01-10	French
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine Environmental & Social Information	2024-01-10	English
FORM 6-K Foreign Filer Report	2024-01-08	English
VALNEVA - Déclaration d’actions et de droits de vote : 31 décembre 2023 Declaration of Voting Results & Voting Rights Announcements	2024-01-05	French
VALNEVA - Declaration of shares and voting rights: December 31, 2023 Declaration of Voting Results & Voting Rights Announcements	2024-01-05	English
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum Report Publication Announcement	2024-01-04	English
Valneva rencontrera des investisseurs lors de la J.P. Morgan Healthcare Conference et du Oddo BHF Forum Investor Presentation	2024-01-04	French

Filings by year

2026 48 filings
2025 157 filings
2024 156 filings
2023 131 filings
2022 206 filings
2021 225 filings
2020 62 filings
2019 86 filings
2018 31 filings
2017 44 filings
2016 63 filings
2015 61 filings
2014 44 filings
2013 90 filings
2012 75 filings
2011 60 filings
2010 51 filings
2009 61 filings
2008 10 filings